Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.France-based pharmaceutical company Ipsen has announced the start of the filing process in Europe of the six-month sustained release formulation of Decapeptyl, a luteinizing hormone releasing hormone agonist developed by Debiopharm for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
Subscribe to our email newsletter
Previously, Ipsen has exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialization rights of the new six-month formulation of Decapeptyl in the world excluding North America, and some other countries like Sweden, Israel, Iran and Japan.